Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nykode Therapeutics AS's Debt-to-EBITDA or its related term are showing as below:
FRA:5VB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.7 Med: -0.1 Max: 0
Current: -0.14
FRA:5VB's Debt-to-EBITDA is ranked worse than 100% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs FRA:5VB: -0.14
Nykode Therapeutics AS (FRA:5VB) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nykode Therapeutics AS Debt-to-EBITDA Related Terms
Nykode Therapeutics AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nykode Therapeutics AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VB vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Nykode Therapeutics AS (FRA:5VB) has a Debt-to-EBITDA of -0.17 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nykode Therapeutics AS. According to the industry distribution chart, Nykode Therapeutics AS ranks #999999 out of 291 companies in the Biotechnology industry.
Is Nykode Therapeutics AS's Debt-to-EBITDA too high?
Nykode Therapeutics AS's current Debt-to-EBITDA is -0.17. Based on the distribution chart, Nykode Therapeutics AS ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Nykode Therapeutics AS in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nykode Therapeutics AS. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Debt-to-EBITDA is -0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.49, compared to a current price of €0.21 — trading 56.9% below its estimated fair value. The current Debt-to-EBITDA is -0.17. Nykode Therapeutics AS's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Debt-to-EBITDA is -0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of €0.21 is trading 56.9% below its estimated GF Value™ of €0.49.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for FRA:5VB:
Debt-to-EBITDA: -0.17
GF Value™: €0.49 vs. price of €0.21 (56.9% below fair value)
No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
43GF Score
Get the complete analysis for FRA:5VB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VB has been successfully added to your 
